Policymakers need to hear directly from patients whose lives are touched by compounded therapies. No organization or industry group can speak with the authenticity, urgency, and lived experience that you can. By sharing your journey, you make the impact personal and impossible to ignore.
Compounding pharmacies provide life-changing, often life-saving, customized medications when FDA-approved drugs are not appropriate or accessible. They fill critical gaps in care that standardized treatments simply cannot meet.
Yet patient access to these therapies is under constant threat from misguided regulations to legal challenges led by the pharmaceutical industry. That’s why it’s vital for patients, prescribers, and compounding pharmacies to join forces through APC and stand united in protecting access to the specialized medications you—and so many others—rely on.
FDA has arbitrarily reclassified Desiccated Thyroid Extract (DTE) as a biologic, prohibiting it from use in compounding and clearing the field for a drugmaker to have a monopoly on the therapy (and surely raise the price).
APC's Blueprint for eliminating redundant, unauthorized, or ineffective regulation that impedes patient access to compounded drugs
Drugmakers have asked FDA to prohibit compounded GLP-1s. If you take compounded tirzepatide or semaglutide, FDA needs to hear from you. Read the facts here, then express your concern in a letter to FDA.
Join the Compounding the Joy of Living Campaign to protect and expand access to pharmacy compounding. Your support helps safeguard compounded therapies, fight regulatory threats, preserve access to critical treatments, and ensure patients’ stories are heard. By contributing, you’re not just funding advocacy—you’re investing in better health outcomes for millions.
.png?width=908&height=106&name=Layer_1%20(1).png)
.png)
.png?width=16&height=16&name=envelope%20(1).png){kind=small}
.png?width=17&height=16&name=folder%20(1).png){kind=small}
.png?width=14&height=13&name=heart_sm%20(1).png){kind=small}